dockets: FDA-2026-P-5122

Regulatory dockets from Regulations.gov — containers for related documents and comments in a rulemaking proceeding.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id agency_id title docket_type last_modified object_id
FDA-2026-P-5122 FDA Requests that the FDA declare that an ANDA may be submitted for, Prazosin Hydrochloride Capsules, USP 3 mg and 4 mg, two strength’s that differ from the currently approved RLD, MINIPRESS (Prazosin Hydrochloride) capsules from PFIZER LABORATORIES DIV PFIZER INC., which FDA approved in 1 mg, 2 mg, and 5 mg strengths prior to Jan 1, 1982 under NDA #017442. Nonrulemaking 2026-05-08T20:33:26Z 0b000064b92c9b66

Links from other tables